These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 12659403

  • 1. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [Abstract] [Full Text] [Related]

  • 2. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [Abstract] [Full Text] [Related]

  • 3. Yasmin: the reason why.
    Thorneycroft IH.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [Abstract] [Full Text] [Related]

  • 4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 5. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH.
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [Abstract] [Full Text] [Related]

  • 6. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R.
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [Abstract] [Full Text] [Related]

  • 7. Added benefits of drospirenone for compliance.
    Foidart JM.
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [Abstract] [Full Text] [Related]

  • 8. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [Abstract] [Full Text] [Related]

  • 9. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R.
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [Abstract] [Full Text] [Related]

  • 10. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E, Skarabis H, Wuttke W, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [Abstract] [Full Text] [Related]

  • 11. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D, Borsos A, Baumgärtner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S.
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [Abstract] [Full Text] [Related]

  • 12. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [Abstract] [Full Text] [Related]

  • 13. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
    Oelkers W.
    Mol Cell Endocrinol; 2004 Mar 31; 217(1-2):255-61. PubMed ID: 15134826
    [Abstract] [Full Text] [Related]

  • 14. Drospirenone and its antialdosterone properties.
    Genazzani AR, Mannella P, Simoncini T.
    Climacteric; 2007 Feb 31; 10 Suppl 1():11-8. PubMed ID: 17364593
    [Abstract] [Full Text] [Related]

  • 15. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle ME, Isaia CF, Petracco A, Peixoto FC, Camargos AF.
    Contraception; 2006 Dec 31; 74(6):446-50. PubMed ID: 17157100
    [Abstract] [Full Text] [Related]

  • 16. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2002 Dec 31; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [Abstract] [Full Text] [Related]

  • 17. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
    Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E.
    Ann N Y Acad Sci; 1995 Jun 12; 761():311-35. PubMed ID: 7625729
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
    De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A.
    Fertil Steril; 2007 Jul 12; 88(1):113-7. PubMed ID: 17418832
    [Abstract] [Full Text] [Related]

  • 19. Use of an oral contraceptive containing drospirenone in an extended regimen.
    Sillem M, Schneidereit R, Heithecker R, Mueck AO.
    Eur J Contracept Reprod Health Care; 2003 Sep 12; 8(3):162-9. PubMed ID: 14667328
    [Abstract] [Full Text] [Related]

  • 20. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S, Foidart JM, Genazzani AR.
    Maturitas; 2006 Nov 20; 55(4):297-307. PubMed ID: 16949774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.